Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Early Sleeve Gastrectomy In New Onset Diabetic Obese Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Procedure: Laparoscopic Sleeve Gastrectomy plus conventional medical therapy;   Drug: Conventional medical therapy
Sponsors:   Azienda Ospedaliera Santa Maria, Terni, Italy;   Ethicon Endo-Surgery
Not yet recruiting - verified June 2015

Multi-centre Peer Support Program in Type 2 Diabetes Patients in Hong Kong

Conditions:   Type 2 Diabetes;   Peer Group
Intervention:   Behavioral: Peer support program
Sponsor:   Chinese University of Hong Kong
Not yet recruiting - verified June 2015

A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care

Conditions:   Pain;   Chronic Pain;   Mental Disorders;   Cardiovascular Diseases;   Diabetes Mellitus, Type 2;   Arthritis
Interventions:   Other: Unblinded to Genetic Testing Results;   Other: Blinded to Genetic Testing Results
Sponsor:   Proove Bioscience, Inc.
Recruiting - verified June 2015

Evaluating the True Magnitude of HYPOglycemic Events After THE Initiation of Sulfonylurea

Condition:   Type 2 Diabetes
Intervention:   Other: Observational
Sponsor:   Institut de Recherches Cliniques de Montreal
Not yet recruiting - verified June 2015

Family-Focused Mobile Health Intervention

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: Family-focused components (FFC);   Behavioral: Individual text messaging
Sponsor:   Vanderbilt University
Not yet recruiting - verified June 2015

Efficacy and Safety of Lobeglitazone Versus Sitagliptin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Lobelitazone 0.5mg;   Drug: Sitagliptin 100mg
Sponsor:   Chong Kun Dang Pharmaceutical
Recruiting - verified May 2015

Complications in Central American Diabetic Patients: Historic Cohort

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: None, observational study
Sponsors:   Clínica Los Yoses;   Novo Nordisk A/S
Not yet recruiting - verified June 2015

Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients

Condition:   Type 2 Diabetes
Intervention:   Drug: Suglat
Sponsor:   Astellas Pharma Inc
Recruiting - verified June 2015

Sustained Effects of a Non-glucidic Nutrient Preload on Glucose Tolerance in Type 2 Diabetes

Condition:   Diabetes
Intervention:   Dietary Supplement: Nutrient preload
Sponsor:   Azienda Ospedaliero, Universitaria Pisana
Not yet recruiting - verified June 2015

Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Type II Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: 5-ALA-SFC;   Drug: Placebo
Sponsor:   SBI Pharmaceuticals Co, Ltd.
Active, not recruiting - verified June 2015

DiaFrail: A Short Duration Study in Older People ( DIAFRAIL Study)

Condition:   Diabetes Mellitus
Interventions:   Drug: Metformin;   Drug: Glimepiride;   Drug: Metformin
Sponsors:   Diabetes Frail Ltd;   Merck Sharp & Dohme Corp.
Not yet recruiting - verified June 2015

Impact of a Virtual Diabetes Self-Care and Education Program on Diabetes-related Outcomes in Latinos With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Behavioral: Virtual Diabetes Self-Care and Education Program;   Device: Fitbit;   Device: Smartphone
Sponsors:   Joslin Diabetes Center;   Verizon Foundation;   Doctors Hospital at Renaissance
Recruiting - verified June 2015

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Not yet recruiting - verified June 2015

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified June 2015

Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: PEX168(100µg);   Drug: PEX168(200µg);   Drug: Placebo;   Drug: Metformin
Sponsor:   Jiangsu Hansoh Pharmaceutical Co., Ltd.
Recruiting - verified May 2015

Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: PEX168(100µg);   Drug: PEX168(200µg);   Drug: Placebo
Sponsor:   Jiangsu Hansoh Pharmaceutical Co., Ltd.
Active, not recruiting - verified January 2015

PASOS: Improving the Health of Immigrant Workers

Conditions:   Overweight and Obesity;   Diabetes
Interventions:   Behavioral: Behavioral Intervention;   Other: Control
Sponsor:   University of California, Davis
Not yet recruiting - verified June 2015

Effects of Polyphenols Found in Pomegranate and Bonolive on Postprandial Blood Glucose in Vivo.

Condition:   Hyperglycaemia
Interventions:   Other: Control (109 g white bread);   Dietary Supplement: Dose 1 (pomegranate or bonolive);   Dietary Supplement: Dose 2 (pomegranate or bonolive)
Sponsor:   University of Leeds
Recruiting - verified June 2015

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Linagliptin;   Drug: Empagliflozin placebo + linagliptin placebo;   Drug: Empagliflozin + linagliptin low dose;   Drug: Linagliptin lacebo;   Drug: Empagliflozin + linagliptin high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2015

The Combined Portfolio Diet and Exercise Study

Conditions:   Cardiovascular Diseases;   Hypercholesterolemia;   Type 2 Diabetes;   Metabolic Syndrome
Interventions:   Behavioral: Portfolio Plus Diet;   Behavioral: DASH-like (high fiber) Diet
Sponsors:   St. Michael's Hospital, Toronto;   Canadian Institutes of Health Research  (CIHR);   University of Toronto;   Laval University;   University of Manitoba;   University of British Columbia
Not yet recruiting - verified June 2015

Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus

Condition:   Diabetes Mellitus Gestational Previous Pregnancy
Intervention:   Behavioral: Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus
Sponsor:   Athabasca University
Not yet recruiting - verified June 2015

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: INSULIN GLARGINE (U100);   Drug: Insulin detemir (Levemir)
Sponsor:   Sanofi
Recruiting - verified June 2015

Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus.

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   AstraZeneca;   Antaros Medical AB;   Bioventure Hub;   43183 Mölndal;   Sweden
Recruiting - verified June 2015

FreeStyle Libre Pro Use in Primary & Secondary Care

Condition:   Diabetes Mellitus
Interventions:   Device: FreeStyle Libre Pro 4 sensor wears, 2 with reviews;   Device: FreeStyle Libre Pro 6 sensor wears, 4 with reviews;   Device: FreeStyle Libre Pro 3 sensor wears
Sponsor:   Abbott Diabetes Care
Recruiting - verified July 2015

The Effect of Dairy and Non-dairy Snacks on Food Intake, Subjective Appetite in Children

Conditions:   Energy Intake;   Appetite
Intervention:   Other: Dietary treatment
Sponsors:   Mount Saint Vincent University;   University of Toronto
Completed - verified June 2015

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Matching Placebo for Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified June 2015

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine;   Drug: insulin aspart
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified June 2015

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

Condition:   Type II Diabetes
Interventions:   Drug: Farxiga;   Drug: Placebo;   Drug: Metformin;   Drug: Insulin
Sponsor:   AstraZeneca
Recruiting - verified June 2015

Impact of CPAP Treatment on Arterial Stiffness in Patients With T2DM and Newly Diagnosed Obstructive Sleep Apnoea

Conditions:   Diabetes;   Obstructive Sleep Apnea
Interventions:   Device: CPAP;   Other: Control
Sponsors:   Nordsjaellands Hospital;   Aarhus University Hospital
Recruiting - verified June 2015

Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: INSULIN GLARGINE (U300) HOE901
Sponsor:   Sanofi
Recruiting - verified June 2015

Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers

Conditions:   Diabetes;   PTH;   Vitamin D;   Fibroblast Growth Factor (FGF23);   Phosphate
Interventions:   Drug: Placebo;   Drug: Canagliflozin
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2015

Effect of Nutritional Counseling Based on Diet Quality on Metabolic Control in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Other: Nutritional Counseling;   Other: Usual Diet Guidance
Sponsor:   Hospital de Clinicas de Porto Alegre
Recruiting - verified June 2015

Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2015

Effects of Physical Exercise on Blood Glucose and Pain From the Muskuloskeletal System in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Exercise training
Sponsor:   Nordsjaellands Hospital
Recruiting - verified February 2015

A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

Conditions:   Type 2 Diabetes;   Chronic Kidney Disease
Interventions:   Drug: ASP8232;   Drug: Placebo
Sponsor:   Astellas Pharma Europe B.V.
Recruiting - verified June 2015

The Role of Phosphodiesterase Inhibitors in Incretin Secretion

Condition:   Healthy Volunteers
Interventions:   Drug: Placebo;   Drug: Roflumilast/Sitagliptin;   Drug: Sitagliptin;   Drug: Roflumilast
Sponsor:   National Institute on Aging (NIA)
Recruiting - verified January 2015

Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?

Condition:   Physical Activity
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   Christopher Bell;   AstraZeneca
Recruiting - verified June 2015

Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: GEMIGLIPTIN LS15-0444;   Drug: vildagliptin;   Drug: metformin
Sponsor:   Sanofi
Recruiting - verified July 2015

Glucose Variability Pilot Study for the Abbott Sensor Based Glucose Monitoring System-Professional

Condition:   Type 2 Diabetes Mellitus
Intervention:   Device: Abbott Sensor Based Glucose Monitoring System-Professional
Sponsor:   Abbott Diabetes Care
Recruiting - verified June 2015

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2015

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine U300 HOE901;   Drug: Insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified June 2015

Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Glibenclamide
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified June 2015

RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes)

Conditions:   Chronic Kidney Disease;   Type 2 Diabetes
Interventions:   Drug: RTA 402;   Drug: Placebo
Sponsor:   Kyowa Hakko Kirin Company, Limited
Recruiting - verified June 2015

Hartmann's Solution and Normal Saline in Type II Diabetes Patients

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Hartmann's solution;   Drug: Normal saline
Sponsor:   Yeungnam University College of Medicine
Recruiting - verified June 2015

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SAR342434;   Drug: insulin lispro;   Drug: insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified June 2015

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Sitagliptin;   Drug: Placebo matching with Saxagliptin;   Drug: Placebo matching with Dapagliflozin;   Drug: Placebo matching with Sitagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified February 2015

Shared Decision Making Between Patients and GPs in the Treatment of Type 2 Diabetes in Primary Care.

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Shared decision making
Sponsor:   UMC Utrecht
Active, not recruiting - verified June 2015

Canola-Mediterranean Diet Study in T2DM

Conditions:   Type 2 Diabetes;   Obesity;   Overweight;   Cardiovascular Diseases
Interventions:   Behavioral: A canola oil enriched mediterranean diet;   Behavioral: A high wheat fiber diet
Sponsors:   St. Michael's Hospital, Toronto;   University of Toronto;   Laval University;   University of Manitoba;   Canola Council of Canada
Recruiting - verified June 2015

Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop

Condition:   Diabetes Mellitus, Type 1
Intervention:   Drug: Sitagliptin
Sponsors:   Albert Einstein College of Medicine of Yeshiva University;   Medtronic
Recruiting - verified May 2015

Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Drug: Insulin Glargine and Insulin Lispro
Sponsors:   GlaxoSmithKline;   PPD
Recruiting - verified June 2015

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   AstraZeneca;   Ono Pharmaceutical Co. Ltd
Recruiting - verified June 2015

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)

Condition:   Type 2 Diabetes
Interventions:   Drug: Mylan's insulin glargine;   Drug: Lantus®
Sponsors:   Mylan Inc.;   Mylan GmbH
Active, not recruiting - verified June 2015

The Effects of Apple Consumption on Cardiovascular Health in Prediabetics andType 2 Diabetics

Conditions:   Diabetes;   Cardiovascular Diseases;   Prediabetes
Interventions:   Dietary Supplement: Apple;   Dietary Supplement: Placebo
Sponsors:   Florida State University;   U.S. Apple Association
Recruiting - verified June 2015

Deep Brain Stimulation for Human Morbid Obesity

Condition:   Obesity
Intervention:   Device: Deep Brain Stimulation
Sponsor:   Hospital do Coracao
Active, not recruiting - verified June 2015

A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis

Condition:   Gastroparesis
Interventions:   Drug: Placebo;   Drug: Camicinal
Sponsor:   GlaxoSmithKline
Recruiting - verified February 2015

Telemonitoring System Study in Participants With Type 2 Diabetes Mellitus (MK-0000-347)

Condition:   Type 2 Diabetes Mellitus
Intervention:   Device: Home telehealth system
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified June 2015

A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin Peglispro;   Drug: Insulin Glargine;   Drug: Insulin Lispro
Sponsor:   Eli Lilly and Company
Completed - verified June 2015

Hypoxia and Exercise in the Elderly

Condition:   Elderly Persons
Interventions:   Other: Hypoxic exercise;   Other: Normoxic Exercise
Sponsors:   Hannover Medical School;   German Diabetes Center
Recruiting - verified June 2015

Ex Vivo Immunotherapy for Hyperglycemia in Type 2 Diabetes Mellitus

Conditions:   Type 2 Diabetes Mellitus;   Hyperglycemia
Intervention:   Drug: ex vivo Activated Immune Cells
Sponsors:   B & Y Technologies;   The 12th People's Hospital of Guangzhou City;   The 12th People's Hospital of Shenzhen City
Recruiting - verified June 2015

A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477

Condition:   Healthy Volunteer, Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: RO6799477
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Comparison Study of Usual Care vs. Usual Care Plus Community Intervention to Manage Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   NIDDM;   Non-insulin Dependent Diabetes Mellitus
Intervention:   Behavioral: Home Visits and Lifestyle Education Support
Sponsors:   McMaster University;   Ontario Ministry of Health and Long Term Care;   Canadian Institutes of Health Research  (CIHR)
Active, not recruiting - verified June 2015

Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Placebo;   Drug: Placebo;   Drug: BI 187004;   Drug: Placebo;   Drug: BI 187004;   Drug: BI 187004;   Drug: BI 187004
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified June 2015

Pyridorin in Diabetic Nephropathy

Conditions:   Diabetic Nephropathy;   Diabetic Kidney Disease
Interventions:   Drug: Pyridorin;   Drug: Placebo
Sponsors:   NephroGenex, Inc.;   Collaborative Study Group (CSG);   Medpace, Inc.
Recruiting - verified June 2015

RetroMASTER - Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes

Condition:   Diabetes
Intervention:  
Sponsors:   NIHR Exeter Clinical Research Facility;   University of Exeter;   Royal Devon and Exeter NHS Foundation Trust;   University of Oxford;   Oxford University Hospitals NHS Trust;   University of Dundee;   NHS Tayside
Active, not recruiting - verified June 2015

PROMASTER - PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes

Condition:   Diabetes
Intervention:   Drug: second- or third-line glucose-lowering diabetes treatment
Sponsors:   NIHR Exeter Clinical Research Facility;   University of Exeter;   Royal Devon and Exeter NHS Foundation Trust;   King's College London;   King's College Hospital NHS Trust;   University of Glasgow;   NHS Greater Glasgow and Clyde;   Newcastle University;   Newcastle-upon-Tyne Hospitals NHS Trust;   Oxford University Hospitals NHS Trust
Active, not recruiting - verified June 2015

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified June 2015

Prucalopride Versus Placebo in Diabetic Gastroparesis

Conditions:   Gastroparesis;   Diabetes Mellitus
Interventions:   Drug: Prucalopride;   Drug: Placebo
Sponsors:   University of Calgary;   Janssen Inc.
Recruiting - verified June 2015

Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Overweight;   Obesity
Interventions:   Drug: Liraglutide;   Drug: Metformin
Sponsor:   University of Miami
Recruiting - verified June 2015

Alzheimer's Disease Biomarkers in Cerebrospinal Fluid in Insulin-resistant Men

Condition:   Alzheimer's Disease
Intervention:  
Sponsors:   University of Eastern Finland;   King's College London;   Sahlgrenska University Hospital, Sweden;   Janssen Pharmaceutica
Enrolling by invitation - verified June 2015

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin 100 mg;   Drug: Canagliflozin 50 mg;   Drug: Canagliflozin 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified June 2015

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 10 mg;   Drug: Glimerpiride;   Drug: Placebo to Ertugliflozin;   Drug: Placebo to Glimepiride;   Drug: Metformin;   Drug: Sitagliptin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified June 2015

A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified June 2015

Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in the Treatment of Type 2 Diabetes Mellitus.

Conditions:   Obesity;   Type 2 Diabetes;   Bariatric Surgery
Interventions:   Procedure: Roux-en-Y gastric bypass;   Procedure: sleeve gastrectomy
Sponsor:   Göteborg University
Recruiting - verified June 2015

Diet and Exercise Intervention in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Optimum Lifestyle Intervention;   Behavioral: Standard Care
Sponsors:   Washington University School of Medicine;   National Dairy Council;   American Egg Board
Recruiting - verified June 2015

A Study of RO6811135 in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Withdrawn - verified July 2015

Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: lixisenatide AVE0010;   Drug: biguanide;   Drug: TZD;   Drug: alpha-GI;   Drug: glinide
Sponsor:   Sanofi
Active, not recruiting - verified June 2015

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta duo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2015

PMS of Trazenta on the Long-term Use as Add-on Therapy

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2015

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Condition:   Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified July 2015

A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2014

Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals

Condition:   Obesity
Intervention:   Drug: Roflumilast
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Suspended - verified August 2014

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation - verified June 2015

Effects of Treating Vitamin D Deficiency in Poorly Controlled Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Vitamin D;   Drug: Placebo
Sponsor:   University of Florida
Completed - verified June 2015

The Empowerment Model Towards Type 2 Diabetic Adults To Enhance Vegetable Intake in Achieving Glycemic Control

Condition:   Glycemic Control for Diabetes Mellitus
Interventions:   Behavioral: Empowerment model to improve dietary intake;   Other: Control group following conventional approach
Sponsor:   SEAMEO Regional Centre for Food and Nutrition
Completed - verified June 2015

Effects of Vildagliptine and Glimepiride on Glucose Variability

Condition:   Diabetes Mellitus, Non-Insulin-Dependent
Interventions:   Drug: Glimepiride;   Drug: Vildagliptin
Sponsor:   Seoul National University Hospital
Recruiting - verified June 2015

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin 5mg
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified June 2015

A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: BMS-813160;   Drug: Placebo matching with BMS-813160
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified April 2015

Better Diabetes Control, Quality - Educate to Achieve Compliance

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified June 2015

A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study to Assess the Safety and Efficacy of MK-3102 in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Placebo to MK-3012;   Drug: Metformin;   Drug: Placebo to metformin;   Drug: Glimepiride
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified July 2015

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition:   Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Lipophilic Micronutrients, Adipokines and Gestational Diabetes Mellitus

Condition:   Gestational Diabetes Mellitus
Intervention:   Other: blood sample
Sponsor:   Assistance Publique Hopitaux De Marseille
Recruiting - verified July 2015

Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: OAD;   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified June 2015

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Placebo matching with Dapagliflozin;   Drug: Saxagliptin;   Drug: Metformin immediate release (IR)
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Completed - verified October 2014

Comparing the Effect of Structured Care Versus Usual Care in Type 2 Diabetes Patients Across the Asia Pacific Region

Condition:   Diabetes
Interventions:   Other: JADE;   Other: DIAMOND
Sponsor:   Asia Diabetes Foundation
Active, not recruiting - verified June 2015

High Calorie Breakfast Versus Fasting in Pre-T2D

Condition:   Type 2 Diabetes
Interventions:   Other: Arm 1 Breakfast;   Other: Arm 2 No Breakfast
Sponsors:   Hospital de Clinicas Caracas;   Tel Aviv University
Active, not recruiting - verified June 2015

Korean Post-marketing Surveillance for Onglyza®

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: No Intervention (subjects were previously treated with Onglyza®)
Sponsor:   Bristol-Myers Squibb
Recruiting - verified June 2015

Impact of Sleep Apnea on Diabetic Foot Wound

Conditions:   Diabetic Foot;   Sleep Apnea
Intervention:   Device: Positive airway pressure therapy
Sponsor:   AGIR à Dom
Recruiting - verified June 2015

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo;   Drug: metformin
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2015

Sitagliptin Dose Determination Study

Condition:   Diabetes Mellitus, Type 1
Intervention:   Drug: Sitagliptin
Sponsor:   Albert Einstein College of Medicine of Yeshiva University
Completed - verified June 2015

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Conditions:   Diabetes Mellitus;   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Metformin;   Drug: Placebo to sitagliptin;   Drug: Placebo to metformin;   Drug: Metformin Rescue;   Drug: Sitagliptin Rescue;   Biological: Insulin Rescue;   Biological: Insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified June 2015

The Metabolic Profile in Intrahepatic Cholestasis of Pregnancy and Diabetes Mellitus

Condition:   Intrahepatic Cholestasis of Pregnancy (ICP), Gestational Diabetes Mellitus (GDM)
Intervention:  
Sponsor:   Imperial College London
Recruiting - verified March 2015

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo matching with Saxagliptin;   Drug: Metformin IR;   Drug: Metformin XR;   Drug: Saxagliptin;   Drug: Saxagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified April 2014

Mifepristone for Metabolic Syndrome

Conditions:   Endocrine Disease;   Diabetes
Intervention:   Drug: Mifepristone
Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2015

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Eli Lilly and Company
Active, not recruiting - verified June 2015

A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: lisinopril;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Biospecimens for Identification of Diseases of the Pancreas.

Conditions:   Pancreatic Cancer;   Chronic Pancreatitis;   Type II Diabetes;   Pancreatic Cysts;   Healthy Control
Intervention:   Procedure: Blood Draw
Sponsor:   University of Michigan
Recruiting - verified June 2015

Risk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified June 2015

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: exenatide;   Drug: placebo
Sponsors:   University of Alabama at Birmingham;   Amylin Pharmaceuticals, LLC.
Recruiting - verified May 2015

A Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6807952
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)

Condition:   Anemia
Intervention:  
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Effectiveness of a Treat-to-target Clinic Led by a Nurse Consultants

Condition:   Diabetes
Intervention:   Other: Structured care led by a nurse consultant
Sponsor:   Asia Diabetes Foundation
Completed - verified May 2011

Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Completed - verified June 2015

The Public Private Partnership Addressing Literacy-Numeracy to Improve Diabetes Care

Condition:   Type 2 Diabetes
Interventions:   Other: Enhanced Diabetes Education;   Other: Standard Diabetes Education
Sponsors:   Vanderbilt University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting - verified June 2015

Effect of Lycopene and Isoflavones on Glucose Metabolism

Conditions:   Metabolic Syndrome;   Diabetes Mellitus, Non-Insulin-Dependent
Interventions:   Drug: Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks;   Other: Screening;   Other: OGTT;   Other: Anthropometrics and Blood pressure;   Other: Screening;   Other: Blood Drawing
Sponsor:   The University of Texas Medical Branch, Galveston
Withdrawn - verified June 2015

New Onset Type 1 Diabetes: Role of Exenatide

Condition:   Type 1 Diabetes
Interventions:   Drug: Exenatide;   Drug: Rapid and long acting insulin;   Drug: long acting insulin + rapid acting + 1.25 mcg Exenatide
Sponsors:   Albert Einstein College of Medicine of Yeshiva University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2015

Insulin Detemir in Obesity Management

Conditions:   Diabetes;   Obesity
Intervention:   Drug: Detemir
Sponsors:   Vanderbilt University;   Novo Nordisk A/S
Active, not recruiting - verified June 2015

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Placebo (Saxagliptin);   Drug: Metformin IR;   Drug: Placebo (Metformin);   Drug: Metformin (Active Rescue)
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified April 2014

Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Active, not recruiting - verified June 2015

Psoriasis Inflammation and Systemic Co Morbidities

Condition:   Psoriasis
Intervention:  
Sponsors:   Rockefeller University;   Weill Medical College of Cornell University
Active, not recruiting - verified June 2015

Risk of Hospitalized Infections Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatment

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified June 2015

Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified June 2015

Risk of Cardiovascular Events in Patients With Type 2 Diabetes Initiating Oral Antidiabetic Treatments

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified June 2015

Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified June 2015

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin glargine;   Drug: metformin;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Terminated - verified July 2015

A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: pioglitazone
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Placebo;   Drug: RO5095932;   Drug: RO5095932
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: pioglitazone;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart 30;   Drug: insulin glargine;   Drug: insulin glulisine
Sponsor:   Novo Nordisk A/S
Completed - verified June 2015

A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO5027838;   Drug: RO5027838;   Drug: RO5093151;   Drug: RO5093151
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Taspoglutide in Type 2 Diabetic Patients

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Sitagliptin Cardiovascular Outcome Study (MK-0431-082)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin phosphate;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Completed - verified June 2015

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin glargine;   Drug: metformin;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: metformin;   Drug: pioglitazone;   Drug: placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Vytorin on Carotid Intima-media Thickness and Overall Rigidity

Condition:   Cardiovascular Diseases
Interventions:   Drug: ezetimibe (+) simvastatin;   Drug: simvastatin;   Drug: pravastatin
Sponsors:   Hospital Universitario 12 de Octubre;   Merck Sharp & Dohme Corp.
Completed - verified August 2008

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: exenatide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

The Role of Small Intestinal Endocrine Cells in Type 2 Diabetic Hyperglucagonemia

Condition:   Type 2 Diabetes
Interventions:   Procedure: Double-balloon enteroscopy;   Other: Standard meal test
Sponsor:   University Hospital, Gentofte, Copenhagen
Completed - verified June 2015

Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy

Conditions:   Birth Defects;   Type 2 Diabetes;   Preterm Birth
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified June 2015

Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: MK0533;   Drug: Comparator: Placebo (unspecified);   Drug: Comparator: pioglitazone
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified June 2015

MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: MK0767
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified June 2015

A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RG1511
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of DPP-IV (3) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4876904
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Actos;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of Aleglitazar in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Actos;   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Glyburide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Simvastatin
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: GK Activator (2)
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: GK Activator (2)
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration

Conditions:   Lipid Metabolism, Inborn Errors;   Hyperlipidemias;   Metabolic Diseases;   Hypolipoproteinemia;   Hypolipoproteinemias;   Hypobetalipoproteinemias;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Congenital Abnormalities;   Metabolic Disorder;   Hypercholesterolemia;   Dyslipidemias;   Lipid Metabolism Disorders
Interventions:   Drug: mipomersen;   Drug: Placebo
Sponsors:   Genzyme, a Sanofi Company;   Isis Pharmaceuticals
Completed - verified June 2015

A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Metformin
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Metformin
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: DPP-IV Inhibitor;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: DPP-IV Inhibitor;   Drug: Metformin;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Evaluation of the Effect of Pramlintide on Satiety and Food Intake

Conditions:   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Intervention:   Drug: Pramlintide acetate
Sponsor:   AstraZeneca
Completed - verified June 2015

Get CardioSmart

You're Invited